Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort

• Published in: Journal of Alzheimer's disease 2016-08, Vol.54 (1), p.287-295
• Main Authors: van Steenoven, Inger, Aarsland, Dag, Weintraub, Daniel, Londos, Elisabet, Blanc, Frédéric, van der Flier, Wiesje M., Teunissen, Charlotte E., Mollenhauer, Brit, Fladby, Tormod, Kramberger, Milica G., Bonanni, Laura, Lemstra, Afina W.
• Format: Article
• Language: English
• Subjects: Age Factors; Aged; Alzheimer Disease - cerebrospinal fluid; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-protein (1-42); Biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Clinical Medicine; Cohort Studies; Dementia with Lewy bodies; Female; Humans; Klinisk medicin; Lewy body disease; Lewy Body Disease - cerebrospinal fluid; Life Sciences; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Mental Status and Dementia Tests; Neurologi; Neurology; Neurons and Cognition; Parkinson Disease - cerebrospinal fluid; Peptide Fragments - cerebrospinal fluid; Phosphorylation; Prevalence; Sex Factors; Tau protein; tau Proteins - cerebrospinal fluid; Time Factors
• ISSN: 1387-2877; 1875-8908; 1875-8908
• DOI: 10.3233/JAD-160322

Background: Concomitant Alzheimer’s disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. Objective: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). Methods: We included 375 DLB patients, 164 Parkinson’s disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau. Results: A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia. Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF. Conclusion: A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.